Market News & Trends
Theolytics Doses First Patient in Phase 1/2a Trial of THEO-260 in Ovarian Cancer
Theolytics has dosed the first patient in its Phase 1/2a multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian…
Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for Manufacturing
Ardena recently announces the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss. Granted by the Dutch Healthcare Authority, the approval enables…
Biolojic Design Joins Johnson & Johnson Innovation - JLABS
Biolojic Design recently announced it is joining the Johnson & Johnson Innovation – JLABS (JLABS) site in Washington, D.C. As part of JLABS @ Washington,…
Gattefossé Announces Inauguration of its New Premises & Technical Center of Excellence in Mumbai
India is a strategic country for the business development of the Gattefossé Group. To support this growing market, Gattefossé continues to invest in the opening…
Steritas Announces Collaboration With argenx to Advance Evidence for Novel Steroid-Sparing Therapeutics
Steritas LLC recently announced a licensing agreement with argenx, a global immunology company, for use of its STOX Suite of steroid-toxicity clinical outcome assessments (COAs)…
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia
GeoVax Labs, Inc. recently announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical…
HCW Biologics & WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics Inc. and WY Biotech Co., Ltd. recently announced they have entered into a worldwide exclusive license agreement to develop and commercialize one of…
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
Trogenix Ltd emerged from stealth mode to unveil its groundbreaking therapeutic platform for treating aggressive cancers. Built from inception by 4BIO Capital, which specializes in…
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences, Inc. recently announced the completion of the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX…
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 IBS
EnteroBiotix Limited recently announced the completion of recruitment in its Phase 2 TrIuMPH (Treating IBS with an Intestinal Microbiota Product for Health) trial assessing the…
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody Achieved 100% Virologic Response & Up To 78% Combined Virologic Response, & ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D
Bluejay Therapeutics recently announced new data from its Phase 2 study of BJT-778, a best-in-class investigational, fully human, high-affinity monoclonal antibody (mAb) that targets hepatitis…
Quotient Sciences Announces Installation of World's First GMP Biofoundry-in-a-Box From Centillion Technology
Quotient Sciences recently announced the installation of Centillion’s proprietary Biofoundry-in-a-Box (BiaB), the first multi-product GMP platform technology for end to end RNA manufacture. BiaB is…
AlveoGene Receives Rare Pediatric Disease Designation Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B Deficiency
AlveoGene recently announced it has been granted a Rare Pediatric Disease Designation (RPDD) by the US FDA for AVG-002, its novel, inhaled gene therapy for…
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury
NurExone Biologic Inc. recently announced the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for the its ExoPTEN therapy, marking a significant step…
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
PTC Therapeutics, Inc. recently announced the US FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy approved…
Aravax Establishes Pharmaceutical Development Base on the Oxford Science Park With a Focus on Developing Manufacturing Capabilities in the UK
Aravax recently announced it has established a UK subsidiary, based on the Oxford Science Park, as the company continues its development into an international leader…
Khondrion Receives FDA Clearance of INDA for Pivotal Phase 3 Trial of Sonlicromanol for Treatment of Primary Mitochondrial Disease
Khondrion recently announced it has received clearance from the US FDA for its Investigational New Drug (IND) application for sonlicromanol. The IND supports the initiation…
AC Immune Reports Positive Interim Results From Phase 2 Trial of Active Immunotherapy in Early Parkinson’s Disease
AC Immune SA recently announced positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein (a-syn)…
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial of a Novel Orexin Receptor 2 Agonist
Nxera Pharma Co., Ltd. recently announced Centessa Pharmaceuticals has initiated a Phase 2 trial of ORX750, an investigational, orally administered, highly potent and selective orexin…
Microbiotica Announces First Patient Dosed in its Phase 1b Trial of a Precision Microbiome Medicine in Ulcerative Colitis Patients
Microbiotica recently announced the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international…
